Tags : PD-L1

Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation

Shots: Tecentriq (atezolizumab, q2w) Intravenous Infusion 840mg has been listed on the NIH reimbursement price list and launched by Chugai as an optimal formulation to treat PD-L1-positive hormone receptor-negative and HER2-negative inoperable or recurrent BC The P-III IMpassion130 study involve assessing of Tecentriq + nab-paclitaxel (albumin-bound) vs nab-paclitaxel (albumin-bound) in patients with unresectable LA/metastatic TNBC […]Read More

Roche Reports Launch of First CDx VENTANA PD-L1 (SP142) Assay

Shots: The launch of VENTANA PD-L1 (SP142) follows the US FDA’s approval in Mar’2019, as the first CDx assay involved in identifying triple-negative breast cancer (TNBC) patients associated with 3 proteins estrogen receptor, progesterone receptor and HER2/neu eligible for treatment with Tecentriq combination The assay is developed for the enhancement of visual contrast of tumor-infiltrating […]Read More

Imfinzi (durvalumab) Receives Positive CHMP Opinion in EU for PD-L1

Shots:  Imfinzi has been approved in unresectable PD-L1 expressing LA NSCLC patients treated with platinum-based CRT Approval is based post-hoc subgroup analyses by PD-L1 expression in addition to PFS & OS results of PACIFIC trial In 2018, AZ received recommendations for Stage III NSCLC US, Canada, Switzerland, India, and Japan based on PACIFIC trial Click here […]Read More